Boston, MA 05/15/2014 (wallstreetpr) – Hemispherx BioPharma, Inc. (NYSEMKT:HEB) is one of the leading pharmaceutical companies of the world. Recently a news came out that the company has entered into a collaborative research agreement with Swiss Department of Defense so that it can test the natural alpha interferon. Please note that that Natural Alpha interferon is the only multi-species available in the USA.
Financial results:
Just before this news was out, Hemispherx BioPharma, Inc. (NYSEMKT:HEB) had announced the financial results for the Q1 ended on 31st March. According to the reports, the net loss reported by the company was $3.836 million in the first three months of the current year. In terms of loss per share, it was $0.02, which is very less as far as the pharmaceutical industry is considered. Please note that the company posted a net loss of $3.611 million in the first quarter of the year 2013.
When it comes to cash, marketable securities and cash equivalents, the company earned total $21.5 million in the first quarter of the current year. The company earned $18.19 million in the previous year’s first quarter as cash, marketable securities and cash equivalents. The management of the company has started focusing on cost minimization and facility enhancement so that the company can grow in the right direction.
Future Prospects:
The main objective of Hemispherx BioPharma, Inc. (NYSEMKT:HEB) is nothing but to provide top notched services to all the customers who are spread in all parts of the world. It is trying to expand its operations in other countries also so that the delivery of services and products can be easier.
The Q1 has not been as good as Hemispherx BioPharma, Inc. (NYSEMKT:HEB) would like to see, as the new quarter has just begun; it has a lot of opportunities where it can improve and enhance the financial performance in the coming months.
